Hepatology

Echosens Highlights New EASL Clinical Practice Guidelines: Unprecedented Recommendation for Non-Invasive FibroScan and Care Management

Thursday, July 22, 2021 - 3:00pm

These guidelines represent a significant advance for the non-invasive management of patients with liver diseases and an unprecedented level of recommendation for Echosens solutions.

Key Points: 
  • These guidelines represent a significant advance for the non-invasive management of patients with liver diseases and an unprecedented level of recommendation for Echosens solutions.
  • Liver stiffness measurement (LSM) by transient elastography (TE) received support from 13 strong recommendations and four other recommendations or supportive statements.
  • Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan, the non-invasive solution for comprehensive management of liver health.
  • Echosens has made FibroScan available in over 100+ countries enabling millions of liver examinations worldwide.

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer

Wednesday, July 21, 2021 - 1:00pm

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer.
  • With ET140203, the ARTEMIS receptor targets an alpha fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells using a TCR-mimic antibody.
  • Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers.

StayWell Charity helps woman with rare liver condition move to Toronto for life-saving liver transplant

Thursday, July 22, 2021 - 12:07am

With her deteriorating liver and no available cure for PBC, her only hope for long-term survival is a liver transplant.

Key Points: 
  • With her deteriorating liver and no available cure for PBC, her only hope for long-term survival is a liver transplant.
  • She turned to social media, garnering awareness for her "Sliver of your Liver" campaign on Facebook in hopes of finding a live liver donor.
  • In support of Breanne's transplant and healing journey, StayWell Charity ( https://staywell.charity ) has launched a crowdfunding campaign to support donations towards her accommodation as she undergoes treatment.
  • "StayWell exists for this very purpose - we're dedicated to helping patients like Breanne access treatment which could make the difference between life and death," wrote Sass Khazzam, Co-CEO of StayWell Charity.

MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Tuesday, July 20, 2021 - 10:21pm

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

Key Points: 
  • Albireo is launching Bylvay immediately to accelerate availability for the patients and families impacted by PFIC.
  • There are an estimated 100,000 patients with cholestatic liver disease without an approved drug treatment.
  • Bylvay is the first drug treatment approved in the U.S. for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC).
  • Progressive familial intrahepatic cholestasis (PFIC) is a rare disorder that causes progressive, life-threatening liver disease.

Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Tuesday, July 20, 2021 - 9:00pm

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

Key Points: 
  • Albireo is launching Bylvay immediately to accelerate availability for the patients and families impacted by PFIC.
  • There are an estimated 100,000 patients with cholestatic liver disease without an approved drug treatment.
  • Bylvay is the first drug treatment approved in the U.S. for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC).
  • Progressive familial intrahepatic cholestasis (PFIC) is a rare disorder that causes progressive, life-threatening liver disease.

Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)

Monday, July 19, 2021 - 1:01pm

As the first non-surgical treatment option, Bylvay represents a fundamental shift in the way PFIC is treated.

Key Points: 
  • As the first non-surgical treatment option, Bylvay represents a fundamental shift in the way PFIC is treated.
  • Of the estimated 100,000 patients with cholestatic liver disease worldwide without an approved drug treatment, there are approximately 15,000 PFIC patients, excluding China and India.
  • Bylvay is the first drug treatment approved in the world for the treatment of all subtypes of progressive familial intrahepatic cholestasis (PFIC).
  • Progressive familial intrahepatic cholestasis (PFIC) is a rare disorder that causes progressive, life-threatening liver disease.

Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021

Monday, July 19, 2021 - 12:00pm

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior to market open on Thursday, July 29, 2021.

Key Points: 
  • NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior to market open on Thursday, July 29, 2021.
  • The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m.
  • Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
  • Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand

Monday, July 19, 2021 - 1:03am

TOKYO, July 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand.

Key Points: 
  • TOKYO, July 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand.
  • Goofice inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon.
  • In Asia (Thailand, Indonesia, Philippines, Malaysia, and Singapore), Eisai is responsible for the commercialization and marketing of this product under a contract with EA Pharma.
  • Eisai will continue to make a further contribution to improve QOL for patients with chronic constipation in Thailand and other Asian countries, through maximization of the product value of Goofice.

Worldwide Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry to 2027 - by Drug, Distribution Channel and Region - ResearchAndMarkets.com

Friday, July 16, 2021 - 5:12pm

The "Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare condition that affects the liver.
  • Increasing awareness about progressive familial intrahepatic cholestasis type 2 disease is expected to provide more opportunities for players in the progressive familial intrahepatic cholestasis type 2 treatment market in the near future.
  • Thus, low healthcare spending in low income countries limits such countries for research and development of new drugs for treatment of rare diseases.

Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus

Wednesday, July 14, 2021 - 2:00pm

The study found that EP547 was safe and well-tolerated in both healthy volunteers and patients with chronic cholestatic or kidney disease at all doses tested.

Key Points: 
  • The study found that EP547 was safe and well-tolerated in both healthy volunteers and patients with chronic cholestatic or kidney disease at all doses tested.
  • EP547 was found to be safe and well-tolerated with no serious adverse events, no adverse events leading to discontinuation, and no safety signals identified.
  • By blocking these pruritogens from activating MrgprX4, Escient believes EP547 has the potential to effectively treat both cholestatic and uremic pruritus.
  • Drug development to address cholestatic and uremic pruritus has been hampered by the lack of basic biological understanding of the relevant mechanisms.